Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Update

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) was the target of a significant growth in short interest in January. As of January 31st, there was short interest totalling 644,000 shares, a growth of 5.1% from the January 15th total of 612,700 shares. Approximately 10.9% of the company’s stock are short sold. Based on an average daily volume of 33,700 shares, the short-interest ratio is presently 19.1 days.

Insider Buying and Selling

In other news, CEO Snehal Patel purchased 2,500 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The stock was acquired at an average cost of $12.51 per share, for a total transaction of $31,275.00. Following the completion of the purchase, the chief executive officer now owns 5,552,502 shares of the company’s stock, valued at approximately $69,461,800.02. This trade represents a 0.05 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders bought 10,500 shares of company stock worth $128,459. Corporate insiders own 51.67% of the company’s stock.

Hedge Funds Weigh In On Greenwich LifeSciences

A number of large investors have recently bought and sold shares of GLSI. Wells Fargo & Company MN lifted its holdings in Greenwich LifeSciences by 54.8% in the fourth quarter. Wells Fargo & Company MN now owns 2,847 shares of the company’s stock worth $32,000 after acquiring an additional 1,008 shares during the last quarter. Brown Brothers Harriman & Co. bought a new position in Greenwich LifeSciences in the fourth quarter worth about $45,000. JPMorgan Chase & Co. lifted its holdings in Greenwich LifeSciences by 172.0% in the fourth quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company’s stock worth $79,000 after acquiring an additional 4,465 shares during the last quarter. Bank of America Corp DE lifted its holdings in Greenwich LifeSciences by 22.3% in the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after acquiring an additional 1,322 shares during the last quarter. Finally, Barclays PLC raised its holdings in shares of Greenwich LifeSciences by 12.7% during the fourth quarter. Barclays PLC now owns 9,648 shares of the company’s stock valued at $108,000 after buying an additional 1,088 shares during the last quarter. Institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Trading Up 0.7 %

NASDAQ GLSI traded up $0.08 during trading hours on Monday, reaching $12.38. The company’s stock had a trading volume of 14,862 shares, compared to its average volume of 34,628. The business has a 50-day simple moving average of $12.60 and a 200 day simple moving average of $13.46. Greenwich LifeSciences has a 52 week low of $9.91 and a 52 week high of $21.44. The stock has a market cap of $162.80 million, a PE ratio of -15.47 and a beta of 1.69.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $38.00 price target on shares of Greenwich LifeSciences in a research note on Tuesday, February 11th.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.